Revolution Medicines said daraxonrasib, its oral RAS inhibitor for metastatic pancreatic ductal adenocarcinoma, more than doubled median overall survival versus chemotherapy in its Phase 3 program. The company’s results immediately translated into major financing momentum. In a follow-on transaction, Revolution priced a $1.5 billion public offering shortly after the trial readout, in what it framed as the largest biopharma follow-on stock sale to date. A separate report described a $2 billion concurrent stock-and-debt package positioned at the top end of recent biotech fundraising activity. For investors and clinical teams, the sequence of efficacy data followed by a scale-up financing underscores how quickly pancreatic oncology capital needs can reprice when late-stage outcomes change the probability of success.